Advice
Following a full submission
ranibizumab (Lucentis®) is accepted for use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Ranibizumab reduces the rate of visual acuity loss and increases visual acuity. It should be stopped if visual acuity falls persistently below 6/60 during treatment.
Download detailed advice99KB (PDF)
Medicine details
- Medicine name:
- ranibizumab 10mg/ml solution for intravitreal injection (Lucentis)
- SMC ID:
- 381/07
- Indication:
- Neovascular (wet) age-related macular degeneration (AMD)
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 11 June 2007